A comparison of the impact of oral capsule hypericum perforatum and matricaria camomil on hot flashes and sleep disorder in perimenopausal women

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201307302751N9

Enrollment

123

Registered

2014-01-20

Start date

2013-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hot flashes and sleep disorder in perimenopausal women. Menopausal and female climacteric states

Interventions

Intervention 1: Control group capsules containing starch, twice a day for 8 weeks. Intervention 2: The first intervention group received 500 mg capsules of chamomile 2 times daily for 8 weeks. Inte

Treatment - Drugs

Control group capsules containing starch, twice a day for 8 weeks

The first intervention group received 500 mg capsules of chamomile 2 times daily for 8 weeks

The second intervention group capsules of Hypericum 900 mg twice a day for 8 weeks

Eligibility

Sex/Gender

Female

Age

45 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Age 45 to 60 years; Having menopausal symptoms for at least 3 months ;Complaining of hot flashes, at least 3 times a day ;Complaining of sleep disturbance for at least 3 months;Total sleep time less than 6 hours ;Not receiving hormone therapy within the last 3 months ;Not receiving treatment for menopause symptoms; Not receiving phytoestrogens such as Soya ;No Heart disease, hypertension, diabetes, epilepsy, any mental illness, thyroid disorders, liver disease, cancer, abnormal uterine bleeding (AUB) ;Not sensitive to any herb; Non-Smoking. Exclusion Criteria :Taking benzodiazepines, hypnotics, anti-coagulants such as aspirin, heparin and warfarin; Not receiving non-hormonal drugs to relieve menopausal symptoms such as clonidine and hormone therapy during the study; Sensitivity to medications used during the study; Not having any systemic disease; Not having tendency to continue the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hot flushing. Timepoint: Baseline, 4 weeks and 8 weeks after. Method of measurement: Daily hot flash form.;Sleep disorder. Timepoint: Baseline, 4 weeks and 8 weeks after. Method of measurement: Pittsburgh Sleep Questionnaire Index.	—

Secondary

Measure	Time frame
No. Timepoint: No. Method of measurement: No.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamaneh Hamzi

School of Nursing and Midwifery Tehran University of Medical Science

SamaneHamzy@yahoo.com+98 21 6105 4219

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026